• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Sanofi, Novo, Lilly Shape up for Big Insulin Fight

Article

Competition is ramping up in the multibillion-dollar market for long-lasting insulins, with Novo Nordisk and Eli Lilly lining up new products that could trump Sanofi's top-seller Lantus.

Worldwide, Lantus has some 80 percent of the market for long-acting, or basal, insulins used to treat diabetes and the product had sales of around $5 billion last year. Now rivals are closing in.

Read the full story:

http://hcp.lv/KahW6a

Source: Reuters

Related Videos
Laxmi Patel screenshot by AJMC
Refat Rasul Srejon, MPH
Refat Rasul Srejon, MPH
Refat Rasul Srejon, MPH
Byoung Chul Cho, MD, PhD
Beth Stein, MD, and Ratna Kiran Bhavaraju-Sanka, MD
Efren Flores, MD
Emma Guttman-Yasskey, MD, PhD
Matias Sanchez, MD
© 2025 MJH Life Sciences
AJMC®
All rights reserved.